Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of “Hold” from Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE) has earned a consensus rating of “Hold” from the seventeen brokerages that are currently covering the firm, Marketbeat.com reports. Fourteen analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $41.00.

SAGE has been the subject of several research reports. Morgan Stanley boosted their price objective on shares of Sage Therapeutics from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Royal Bank of Canada boosted their target price on shares of Sage Therapeutics from $21.00 to $26.00 and gave the company a “sector perform” rating in a research report on Thursday, February 15th. JPMorgan Chase & Co. boosted their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, March 26th. StockNews.com upgraded shares of Sage Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. Finally, HC Wainwright boosted their target price on shares of Sage Therapeutics from $25.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th.

Hedge Funds Weigh In On Sage Therapeutics

Institutional investors have recently bought and sold shares of the stock. MetLife Investment Management LLC purchased a new position in Sage Therapeutics during the first quarter valued at $34,000. CWM LLC grew its stake in Sage Therapeutics by 274.2% during the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 883 shares in the last quarter. KBC Group NV purchased a new position in Sage Therapeutics during the fourth quarter valued at $28,000. China Universal Asset Management Co. Ltd. grew its stake in Sage Therapeutics by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 748 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Sage Therapeutics during the first quarter valued at $209,000. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Stock Performance

Shares of Sage Therapeutics stock opened at $15.63 on Friday. The stock has a market capitalization of $939.52 million, a PE ratio of -1.73 and a beta of 0.86. Sage Therapeutics has a 52-week low of $15.06 and a 52-week high of $59.99. The company has a 50-day simple moving average of $20.47 and a two-hundred day simple moving average of $21.05.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.28) by $0.73. The business had revenue of $77.97 million during the quarter, compared to analysts’ expectations of $60.15 million. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. The business’s revenue for the quarter was up 2621.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.47) earnings per share. As a group, equities research analysts forecast that Sage Therapeutics will post -6.05 EPS for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.